Heart failure (HF) is a clinical manifestation caused by various cardiovascular pathologies. It is characterized by the heart's inability to pump sufficient oxygenated blood to the body. HF is associated with a general deterioration in quality of life and a high rate of hospitalization and mortality. HF Severity is classified according to the New York Heart Association (NYHA) classification groups:

  • NYHA Class I: No symptoms and no limitation in physical activity

  • NYHA Class II: Mild symptoms, mild shortness of breath and/or angina, mild
       limitation to physical activity

  • NYHA Class III: Marked limitation in physical activity caused by symptoms,
       decreased physical capacity, only comfortable at rest

  • NYHA Class IV: Severe limitation to physical activity, experiences symptoms
       while at rest, mainly hospitalized patients

 

HF can be further divided into subcategories based on the patient's ejection fraction (EF). Three subcategories have been accepted to date: Heart failure with reduced ejection fraction (HFrEF), heart failure with intermediate ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF). For HFrEF, and to some extent HFmrEF, there are well-established treatment strategies that effectively reduce morbidity and outcome. Conversely, specific biomarkers and treatments for HFpEF patients are urgently needed.

The most common causes of HF, regardless of subtype, include coronary artery disease, previous myocardial infarction(s), hypertension, arrhythmia, and cardiomyopathy.

Cardiac fibrosis is an underlying process in all types of HF. HF often develops in patients with previous MI. MI is characterized by a reparative phase after the event, leading to increased deposition of collagen and other ECM proteins in the myocardium. Cardiac fibrosis, characterized by dynamic remodeling of extracellular matrix (ECM) proteins (Figure 1), plays an important role in the pathogenesis of HFpEF. Therefore, understanding the balance of ECM protein formation and degradation in HF is critical.


Heart Failure with Preserved Ejection Fraction (HFpEF) is a subtype of Heart Failure, in which patients have an EF of more than 50%, and it is predicted to be the predominant form of HF in the coming years. The clinical manifestation of HFpEF is similar to other types of HF. HFpEF is a complex pathology that is influenced by the severity of concomitant diseases such as diabetes, obesity, and hypertension. HFpEF is highly influenced by cardiac fibrosis, which is triggered by extrinsic factors such as diabetes and hypertension. Cardiac fibrosis, in combination with other processes, contributes significantly to the pathogenesis of HFpEF.

How many people have heart failure with preserved ejection fraction?
It is estimated that HF affects approximately 26 million people worldwide, and the number of HF patients is expected to continue to rise. In the United States, approximately 915,000 new cases are reported annually, affecting about 10 out of every 1000 people in the population. In Europe, the incidence rate is calculated to be approximately 4 per 1000 affected HF. The incidence rate of HFpEF is steadily increasing, and approximately 50% of HF patients have HFpEF.

How is heart failure diagnosed with preserved ejection fraction?
The diagnosis of HFpEF is troublesome. If HFpEF is suspected in a patient, EF and end-diastolic volume are determined. If abnormalities are found, the patient is referred for hemodynamic measurements, tissue Doppler, and biomarker analysis. Most commonly, HF is diagnosed by chest radiography, electrocardiogram (ECG), measurement of brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT -proBNP), or cardiac catheterization.

During clinical examination, a combination of these diagnostic tools is usually used to accurately diagnose the patient. NT -proBNP remains to date the best noninvasive biomarker for diagnosis and prognosis in HFpEF patients.

How is heart failure with preserved ejection fraction treated?
Despite numerous attempts and advances in HFpEF research, no effective treatment has been shown to specifically reduce morbidity and mortality in HFpEF. The current treatment strategy is based on reducing the burden of comorbidities such as obesity, hypertension, and diabetes.

The most commonly used drugs for the treatment of HFpEF include angiotensin-converting enzyme inhibitors (ACE), angiotensin II receptor blockers (ARBs), beta blockers, and diuretics. Recent studies have examined the effect of mineralocorticoid receptor agonists such as spironolactone, but a consistent reduction in mortality or hospitalization in HFpEF patients has yet to be demonstrated.

The first step in diagnosing HFpEF is the evaluation of EF combined with the measurement of NT-proBNP. However, patients may not present a clear reduction in EF; additionally, NT-proBNP is reported to fluctuate in HFpEF patients depending on obesity, a common condition in HFpEF patients. This means that NT-proBNP is not an accurate biomarker in obese patients. There is a need for non-invasive biomarkers accurately reflecting the risk of developing HFpEF as well as being able to diagnose HFpEF patients irrespective of comorbidities. A strategy of “one biomarker fits all” is not applicable in HFpEF patients, and the future of diagnosis and risk assessment in HFpEF may be a combination of biomarkers.

Visit our cardiovascular biomarker portfolio and choose a panel that fits your clinical research or drug development targets!

Cardiac fibrosis is one of the causes of HFpEF. Quantification of ECM turnover in HFpEF patients may provide unique insight into structural and functional ECM changes relevant to HFpEF pathogenesis. Moreover, it is possible that an increase in ECM protein deposition precedes the functional changes that can be detected by currently available diagnostic techniques. Therefore, Protein Fingerprint Technology cardiac biomarkers may provide an earlier detection of HFpEF.

Several collagens are upregulated in cardiac fibrosis, as the increased levels of cardiac biomarkers of collagen formation in patients with cardiac fibrosis show (figure 1).  A biomarker reflecting formation of type VI collagen (PRO-C6), has emerged as a promising biomarker for outcome in HFpEF. PRO-C6 also measures the deleterious signaling molecule endotrophin (released from type VI collagen), which may play a direct role in HFpEF pathogenesis.

In an analysis of a subset of the TOPCAT trial, PRO-C6 significantly predicted risk of mortality and rehospitalization due to heart failure, with greater statistical significance than NT-proBNP and the MAGGIC composite risk score (figure 2).

Higher degradation of titin (TIM) was shown to be significantly associated with a lowered functional capacity in HFpEF patients, and degradation markers of both titin and type I collagen (C1M) were significantly prognostic for risk of readmission in HFpEF patients.

Diagnostic Protein Fingerprint Technology biomarkers for cardiac fibrosis

PRO-C3, PRO-C6, PRO-C8

C3M, C4M, C5M, C6M

Prognostic Protein Fingerprint Technology biomarkers for HFpEF

TIM, C1M, PRO-C6

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.